Tuesday, November 27, 2012
Deerfield based business has been in talks for a year to buy Swedish concern.
Deerfield based Baxter International, Inc., a maker of blood therapy, kidney dialysis and other products, is close to a deal to purchase Swedish kidney dialysis maker Gambro AB for $4 billion, according to a report on MoneyNews. Gambro is owned by two Nordic private equity firms, according to the MoneyNews article. That report indicates the two businesses want to ink the deal in two to three weeks. The deal transaction will enhance Baxter’s kidney dialysis efforts. Get local news in a daily email from Patch. It's like getting a free newspaper. Learn more. If the deal is completed, which is not definite based on a report on Reuters, it would boost Baxter’ share of the renal business market. The renal portion of the Deerfield based company …
Friday, April 20, 2012
Deerfield based company profits show three percent increase.
Deerfield based Baxter International exceeded Wall Street expectations Thursday when it announced profits three percent greater than the same period a year ago, according to a report on NASDAQ. The company posted net income of $588 million or $1.04 per share for the first quarter, higher than $570 million or $0.98 per share in the prior-year quarter. On average, 16 analysts polled by Thomson Reuters expected the company to report earnings of $1.00 per share for the first quarter. Sales for the first quarter increased three percent to $3.39 billion from $3.28 billion in the same period of 2011, and surpassed expert analysts' consensus revenue estimate of $3.30 billion. Excluding the impact of foreign exchange, sales grew four percent.
Wednesday, April 18, 2012
Earnings period ended before FDA request for more information on new drug before approval sent shares lower.
Wall Street experts expect earnings for Deerfield based Baxter International to increase one percent from the same period a year ago to 99 cents per share, according to a report Tuesday in the Wall Street Journal. The earnings report is due out Thursday. In other news about Baxter, shares fell five percent Monday because the Food and Drug Administration is requiring additional information before approving one of its new products, HyQ, according to reports in the Chicago Tribune. The FDA wants more information on HyQ, an experimental drug designed to help the human immune system. The product is being developed in partnership with Halozyme Therapeutics of California. Baxter had hoped to move ahead with the product in the first half of this …
